XML 45 R35.htm IDEA: XBRL DOCUMENT v3.19.2
Basis of Presentation (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Mar. 01, 2019
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Net loss   $ 29,387,226 $ 6,639,125 $ 58,606,488 $ 38,989,953  
Working capital   86,400,000   86,400,000    
Retained earnings (accumulated deficit)   (679,032,924)   (679,032,924)   $ (620,426,436)
Cash, cash equivalents, and short-term investments   106,000,000   106,000,000    
Long-term investments   $ 8,500,000   8,500,000    
Proceeds from issuance of stock       $ 2,296,316 $ 1,973,401  
Geneos Therapeutics, Inc.            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Non-controlling interest   39.00%   39.00%    
VGX Animal Health, Inc            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Non-controlling interest   15.00%   15.00%    
Common stock | Sales Agreement            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Stock sales agreement, remaining authorized sales amount   $ 69,700,000   $ 69,700,000    
Proceeds from issuance of stock   1,400,000   2,300,000   $ 29,200,000
6.50% Convertible Senior Notes Due 2024 | Convertible Debt            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Proceeds from issuance of debt $ 75,700,000     75,700,000    
Principal amount $ 78,500,000.0 $ 78,500,000.0   $ 78,500,000.0    
Debt instrument, interest rate, stated percentage 6.50% 6.50%   6.50%